What the studies say: signal and uncertainty

In a 2024 Nature Medicine study of 30 veterans, depression symptoms fell 87% at 1 month; in that same study, PTSD symptoms fell 88% and anxiety 81% at 1 month, with reported 83%–86% remission rates across key symptom domains at that time point. A prior ibogaine cohort consolidated in review included 191 patients with opioid and cocaine addiction treated with a single 10–12 mg/kg dose, where mean depression scores fell from above the clinical threshold to minimal symptoms at 1 month.

In the same review, only 16.7% of patients said they would repeat the ibogaine experience, suggesting low abuse liability. Nature also reported that the current literature remains dominated by observational studies without controls, and a 2000 prospective study alongside later review‑based synthesis form much of the historical clinical evidence cited by Medscape. For those following clinical services, some programs emphasize ibogaine treatment for addiction while monitoring mood changes as a secondary outcome.

30 veterans in 2024 saw large short‑term symptom reductions across depression, PTSD, and anxiety at 1 month.

10–12 mg/kg single‑dose regimens appear in prior addiction cohorts with mood score shifts at 1 month.

Observational designs remain dominant; randomized controlled trials have not yet established efficacy for depression.

Safety, screening, and known risks

Ibogaine carries meaningful medical risk. The safety debate—especially QT prolongation and fatal arrhythmias—remains unresolved. A 2012 review led by Alper identified 19 fatalities after ibogaine ingestion between 1990 and 2008, and Medscape says later updates raised the total to 33 deaths reported in the medical literature.

Ibogaine’s long duration (>24 hours) and noribogaine’s 20–27 hour half‑life underscore the need for extended monitoring in clinical research settings. Despite growing attention, ibogaine remains unapproved and Schedule I in the United States while federal policy shifts are creating new research and potential access pathways.

Deep dive: study notes and scope

The recent veteran study (Nature Medicine, 2024) reported large 1‑month effect sizes across depression, PTSD, and anxiety, with remission rates in the 83%–86% range at that time point. Nature has cautioned that ibogaine remains scientifically mysterious and hazardous, and that observational studies without controls currently dominate the literature.

In earlier cohorts focused on addiction (191 patients; 10–12 mg/kg), mean depression scores moved from above the clinical threshold to minimal symptoms at 1 month. A historical 2000 prospective study and later review‑based synthesis are frequently cited by Medscape for depression and craving effects. Together, these data suggest a signal of benefit alongside high uncertainty and real medical risk.

FAQ

Does ibogaine work for depression?

The evidence is preliminary. Observational data suggest rapid symptom reductions at 1 month in specific contexts (for example, a 2024 veteran cohort), but there are no randomized controlled trials establishing efficacy for depression. The appropriate framing is a signal of benefit amid high uncertainty and meaningful risk.

Is ibogaine approved or legal in the U.S.?

Ibogaine is a Schedule I substance and remains unapproved. A federal order on April 18, 2026 directed HHS/ARPA‑H to allocate at least $50 million for serious mental illness research and asked FDA/DEA to facilitate a Right to Try pathway for eligible patients, but that does not equate to approval.

What are the main safety concerns?

Cardiac risk is central—particularly QT prolongation and potential fatal arrhythmias. A 2012 review identified 19 fatalities between 1990 and 2008, and later updates in the medical literature have cited 33 deaths. Long duration (>24 hours) and a noribogaine half‑life of 20–27 hours also mean extended monitoring is relevant in research contexts.

How long does ibogaine last, and what dose is studied?

The acute altered state often exceeds 24 hours. Noribogaine’s half‑life ranges from 20 to 27 hours. Prior addiction cohorts have used single 10–12 mg/kg dosing. For preparation and formulation background, some readers consult HCl formulation guidance resources.

Is depression ever a primary indication?

The depression question is usually not ibogaine as a first‑line antidepressant. Rather, researchers ask whether it may reduce depressive symptoms rapidly in people with severe comorbidity, particularly addiction or trauma, while acknowledging the preliminary and observational nature of current evidence. For broader clinical context, see an addiction-focused ibogaine overview discussions.